SOURCE: Pharming Group N.V.

January 31, 2007 05:41 ET


LEIDEN, NETHERLANDS -- (MARKET WIRE) -- January 31, 2007 -- Biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) announced today that its inclusion in the Amsterdam Small cap index (AScX) and removal from the Amsterdam Midkap index has been confirmed by Euronext Indices BV (Euronext).

The AScX is composed of the top 25 actively traded small caps on Euronext Amsterdam, following the top 25 mid cap companies. The companies in AScX are selected for the index based on value of full year 2006 turnover of shares in euros. The inclusion of Pharming will take effect on March 2, 2007.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (MAA under review by EMEA) and human lactoferrin for use in food products (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with NovaThera) and DNA repair (via its acquisition of DNage BV). Additional information is available on the Pharming website, and on

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.


Carina Hamaker (NL)              Rein Strijker (NL)
Investor Voice                   Pharming Group NV
T: +31 (0)6 537 49959            T: +31 (0)71 524 7434
T: +31 (0)71 524 7431

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information